Jim Cramer on Eli Lilly: "We Like It"

Eli Lilly and Company (NYSE:LLY) is one of the 17 stocks that Jim Cramer commented on. Cramer showed a positive sentiment toward Eli Lilly and Company (NYSE:LLY), as he remarked, “Eli Lilly, what can I say? That’s medicine. We like it.”

Eli Lilly (NYSE:LLY) develops and markets a broad range of pharmaceuticals for conditions such as diabetes, obesity, cancer, autoimmune diseases, and neurological disorders. The company also engages in research collaborations to advance treatments. During a May episode, Cramer recommended buying more of the company’s stock and said that he would buy the stock “hand over fist.”

“I want you to buy more… The reason why you want to buy it is because there was definitive data that came out last night about Novo Nordisk not being anywhere near as good as Eli Lilly when it comes to weight loss, which is what a lot of people are in the GLP for. And it was not reflected because the things were so crazed because of what the president announced. I think the stock could be up a hundred points when people realize, wait a second, it is definitively better than Novo. I would buy Eli Lilly hand over fist.”

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.